SenesTech, Inc. (SNES) 주식 분석

회사 개요

SenesTech, Inc. is a specialized entity focused on the development and commercialization of technologies designed to manage animal pest populations through fertility control mechanisms. The company operates within the Basic Materials sector, specifically targeting the Specialty Chemicals industry, which implies its core business revolves around manufacturing and distributing specific chemical compounds like 4-vinylcyclohexene diepoxide and triptolide found in its product lines. As of the latest data, the company maintains a market capitalization of $8.49M and employs a workforce of 23 individuals to support its operations. The annual revenue for the trailing twelve months stands at $2.22M, indicating that SenesTech functions as a micro-cap enterprise with a very limited revenue base relative to larger industrial peers. This small market capitalization and modest revenue figure suggest that the company is likely in a niche market position where it faces significant headwinds in scaling production or expanding its customer base beyond its current specialized applications.

재무 건전성

The company reported a revenue of $2.22M for the trailing twelve months, yet simultaneously recorded a net income of $-6,383,000 and an EBITDA of $-6,370,000. The substantial gap between the positive revenue of $2.22M and the significant net loss of approximately $6.4M reveals a highly volatile cost structure where operating expenses and cost of goods sold far exceed the gross inflows from sales. Consequently, the free cash flow stands at $-3,711,375, which indicates a severe lack of financial flexibility and suggests that the company is burning through its liquidity reserves to sustain its R&D and commercialization efforts. Regarding profitability metrics, the gross margin is reported at 62.5%, while the operating margin is negative at -446.8% and the profit margin is -287.4%, highlighting that despite efficient production costs relative to sales, overhead and general expenses are disproportionately high. The balance sheet shows a cash position of $8.57M against total debt of $2.68M, resulting in a debt-to-equity ratio of 27.98, which suggests a leverage profile that relies heavily on equity financing rather than debt obligations. However, the current ratio of 12.61 indicates an extremely high level of short-term liquidity, meaning the company possesses ample current assets to cover its short-term liabilities without immediate risk of insolvency. Furthermore, the Return on Equity is -105.7% and the Return on Assets is -50.4%, revealing that management's current effectiveness in generating profits from shareholder capital and total assets is negative due to the ongoing operational losses.

밸류에이션 평가

The valuation metrics present a complex picture given the lack of traditional earnings, with the P/E Ratio (TTM) listed as N/A and the Forward P/E at -0.36. The negative Forward P/E of -0.36 implies that analysts or market models project the company will remain unprofitable in the near term, creating a scenario where traditional earnings-based valuation multiples are not applicable. The price-to-book ratio stands at 0.87, indicating that the market values the company at a discount relative to its book value, which often signals that the market expects poor future performance or significant asset impairment. Alternatively, the price-to-sales ratio of 3.82 and the EV/EBITDA of -0.41 provide alternative perspectives, suggesting that the market is pricing the company based on revenue potential rather than profitability, although the negative EV/EBITDA reinforces the expectation of continued losses. The stock has traded within a 52-week range between a low of $1.31 and a high of $6.24, meaning the current trading price sits significantly below the 52-week high and reflects the market's cautious stance on the firm's ability to reverse its loss trajectory. The beta value is recorded at 0.25, which indicates that the stock exhibits very low price volatility relative to the broader market, moving much less aggressively than the overall index.

Growth & Income

SenesTech, Inc. is experiencing a contraction in top-line performance, with a revenue growth rate of -16.0% year-over-year, while earnings growth is listed as N/A due to the absence of prior year profits. Since the company is currently unprofitable, the concept of earnings growing faster or slower than revenue is moot, as the primary challenge is turning the revenue decline or stagnation into a path toward profitability rather than scaling earnings growth. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the company reinvests all available cash flows, albeit negative ones, into its core operations and technology development rather than returning capital to shareholders. The overall growth and income profile is characterized by declining revenue, significant negative earnings, and zero dividend distribution, painting a picture of a high-risk investment vehicle that relies entirely on future operational improvements to generate positive cash flows.